Revenue (TTM) Chart

View Revenue (TTM) for XGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (TTM) Chart
Start Trial

Historical Revenue (TTM) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 71.12M
March 31, 2026 68.38M
December 31, 2025 66.58M
September 30, 2025 63.60M
June 30, 2025 58.86M
March 31, 2025 56.72M
December 31, 2024 55.64M
September 30, 2024 55.75M
June 30, 2024 56.66M
March 31, 2024 55.73M
December 31, 2023 52.55M
September 30, 2023 51.62M
June 30, 2023 52.93M
March 31, 2023 46.40M
December 31, 2022 45.56M
September 30, 2022 45.42M
June 30, 2022 42.94M
March 31, 2022 48.11M
December 31, 2021 48.30M
September 30, 2021 48.28M
June 30, 2021 46.80M
March 31, 2021 42.98M
Date Value
December 31, 2020 41.98M
September 30, 2020 39.52M
June 30, 2020 39.18M
March 31, 2020 40.71M
December 31, 2019 40.39M
September 30, 2019 39.81M
June 30, 2019 37.60M
March 31, 2019 34.90M
December 31, 2018 32.44M
September 30, 2018 27.25M
June 30, 2018 23.68M
March 31, 2018 20.37M
December 31, 2015 17.95M
September 30, 2015 17.74M
June 30, 2015 16.75M
March 31, 2015 14.64M
December 31, 2014 11.66M
September 30, 2014 8.518M
June 30, 2014 5.781M
March 31, 2014 4.088M
December 31, 2013 3.055M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (TTM) Range, Past 5 Years

View Revenue (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (TTM) Benchmarks

View Revenue (TTM) Benchmarks
Start Trial
Myriad Genetics, Inc. 806.60M
BioRestorative Therapies, Inc. 0.3579M
CareDx, Inc. 458.09M
Natera, Inc. 2.707B
Sera Prognostics, Inc. 0.07M